tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2021 Jul 15.
doi: 10.1111/irv.12889. Online ahead of print.
Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt
Amira S El Rifay[SUP] 1 2 [/SUP], Sara H Mahmoud[SUP] 1 [/SUP], Mohamed A Marouf[SUP] 1 [/SUP], Mokhtar R Gomaa[SUP] 1 [/SUP], Ahmed El Taweel[SUP] 1 [/SUP], Noura M Abo Shama[SUP] 1 [/SUP], Mohamed GabAllah[SUP] 1 [/SUP], Soha M Abd El Dayem[SUP] 3 [/SUP], Ahmed Kandeil[SUP] 1 [/SUP], Ahmed Mostafa[SUP] 1 [/SUP], Rabeh El-Shesheny[SUP] 1 [/SUP], Ghazi Kayali[SUP] 4 5 [/SUP], Mohamed A Ali[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Reported laboratory-confirmed COVID-19 cases underestimate the true burden of disease as cases without laboratory confirmation, and asymptomatic and mild cases are missed by local surveillance systems. Population-based seroprevalence studies can provide better estimates of burden of disease by taking into account infections that were missed by surveillance systems. Additionally, little is known about the determinants of seroconversion in community settings.
Methods: We conducted a cross-sectional serologic survey among 888 participants in Egypt.
Results: Neutralizing antibodies were detected in 30% of study volunteers. Age and educational level were associated with being seropositive as people older than 70 years and people with graduate degrees had lower seroprevalence. Self-reporting cases having COVID-19-related symptoms such as fever, malaise, headache, dyspnea, dry cough, chest pain, diarrhea, and loss of taste or smell were all associated with having antibodies. Fever and loss of taste or smell were strong predictors with odds ratios of 2.1 (95% confidence interval: 1.3-3.5) and 4.5 (95% confidence interval: 2.6-7.8), respectively.
Conclusions: Our results can guide COVID-19 prevention and control policies and assist in determining the immunity level in some Egyptian communities.
Keywords: COVID-19; Egypt; SARS-CoV-2; covariates; neutralizing antibodies; seroprevalence.
. 2021 Jul 15.
doi: 10.1111/irv.12889. Online ahead of print.
Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt
Amira S El Rifay[SUP] 1 2 [/SUP], Sara H Mahmoud[SUP] 1 [/SUP], Mohamed A Marouf[SUP] 1 [/SUP], Mokhtar R Gomaa[SUP] 1 [/SUP], Ahmed El Taweel[SUP] 1 [/SUP], Noura M Abo Shama[SUP] 1 [/SUP], Mohamed GabAllah[SUP] 1 [/SUP], Soha M Abd El Dayem[SUP] 3 [/SUP], Ahmed Kandeil[SUP] 1 [/SUP], Ahmed Mostafa[SUP] 1 [/SUP], Rabeh El-Shesheny[SUP] 1 [/SUP], Ghazi Kayali[SUP] 4 5 [/SUP], Mohamed A Ali[SUP] 1 [/SUP]
Affiliations
- PMID: 34264010
- DOI: 10.1111/irv.12889
Abstract
Background: Reported laboratory-confirmed COVID-19 cases underestimate the true burden of disease as cases without laboratory confirmation, and asymptomatic and mild cases are missed by local surveillance systems. Population-based seroprevalence studies can provide better estimates of burden of disease by taking into account infections that were missed by surveillance systems. Additionally, little is known about the determinants of seroconversion in community settings.
Methods: We conducted a cross-sectional serologic survey among 888 participants in Egypt.
Results: Neutralizing antibodies were detected in 30% of study volunteers. Age and educational level were associated with being seropositive as people older than 70 years and people with graduate degrees had lower seroprevalence. Self-reporting cases having COVID-19-related symptoms such as fever, malaise, headache, dyspnea, dry cough, chest pain, diarrhea, and loss of taste or smell were all associated with having antibodies. Fever and loss of taste or smell were strong predictors with odds ratios of 2.1 (95% confidence interval: 1.3-3.5) and 4.5 (95% confidence interval: 2.6-7.8), respectively.
Conclusions: Our results can guide COVID-19 prevention and control policies and assist in determining the immunity level in some Egyptian communities.
Keywords: COVID-19; Egypt; SARS-CoV-2; covariates; neutralizing antibodies; seroprevalence.